DeepMatter has appointed Bryn Roberts to its board as Non-Executive Director with effect from August 2021.
Roberts brings 15 years of experience in the pharmaceutical sector. He is currently SVP and Head of Data Services at Roche Information Solutions and until recently was Global Head of Operations, Pharmaceutical Research & Early Development. As a member of the team, he worked on data science and laboratory automation, including applications of digital and artificial intelligence (AI) technologies.
DeepMatter will seek to leverage his knowledge to further develop its data platforms and ensure they meet the needs of the pharmaceutical industry, supporting increased reproducibility, predictability and sustainability.
Roberts is a Fellow at the University of Oxford, an Associated Faculty member with the University of Frankfurt Big Data Lab, lectures in medical informatics at the University of Applied Sciences, Switzerland and sits on various advisory boards. He has previously been recognised in the Fierce Biotech IT list of Top 10 Biotech Techies and the Top 50 Big Data Influencers in Precision Medicine by the Big Data Leaders Forum.
Karen Bach, Non-Executive Chair of DeepMatter Group, commented: "I am delighted to welcome Bryn to DeepMatter. To have such a credible industry expert on the Board is a great vote of confidence in our team and we look forward to tapping into his wealth of insight and expertise to drive our offerings forward. An inspiring leader in the world of informatics, who is pushing the field in novel data-driven healthcare approaches, Bryn is a perfect fit for DeepMatter where we enable scientists to use data to discover and develop medicines that transform patients’ lives, reliably and cost effectively. His expertise will be invaluable as we continue in our goal of integrating chemistry with technology by building and commercialising powerful data platforms.”
Bryn Roberts, SVP & Global Head of Data Services at Roche, added: “My career goal is to drive and enable the delivery of innovative healthcare solutions that address a significant unmet need. The value of data captured directly in the lab via DeepMatter and the insights the industry can extract from them will spur further innovation. I am excited to be joining DeepMatter as my first commercial Non-Executive position and look forward to helping them on their journey to accelerate scientific computing in the pharma industry.”